Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash from Investing Activities (2016 - 2025)

Vistagen Therapeutics' Cash from Investing Activities history spans 12 years, with the latest figure at $104000.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 124.64% year-over-year to $104000.0; the TTM value through Dec 2025 reached -$251000.0, up 98.17%, while the annual FY2025 figure was -$13.1 million, 21454.1% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was $104000.0 at Vistagen Therapeutics, up from -$94000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $527000.0 in Q1 2025 and bottomed at -$7.8 million in Q3 2024.
  • The 4-year median for Cash from Investing Activities is -$121950.0 (2021), against an average of -$1.2 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 1218.75% in 2024 before it soared 1917.24% in 2025.
  • A 4-year view of Cash from Investing Activities shows it stood at -$200400.0 in 2021, then soared by 84.03% to -$32000.0 in 2023, then crashed by 1218.75% to -$422000.0 in 2024, then soared by 124.64% to $104000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Cash from Investing Activities are $104000.0 (Q4 2025), -$94000.0 (Q3 2025), and -$788000.0 (Q2 2025).